阮建清脉方促进骨髓间充质干细胞的迁移和增殖。
Ruan Jian Qing Mai's Formula Promotes Bone Marrow-Derived Mesenchymal Stem Cell Migration and Proliferation.
出版信息
Altern Ther Health Med. 2023 Nov;29(8):172-177.
OBJECTIVE
To investigate the response of (BM-MSCs) to the Ruan Jian Qing Mai formula (RJQM) in the treatment of atherosclerotic occlusion (ASO), and consequently promoting the development of collateral circulation and angiogenesis.
METHOD
35 male rats were randomly assigned to 6 experimental groups and A control group. 0.9% NaCl solution and 2.7, 5.4, 10.8, 16.2, 21.6, and 27 g × kg-1 × d-1 of RJQM formula were gavaged to the experimental groups twice a day for 8 days. After the last administration, medicated serum was prepared from the blood collected from the abdominal aorta. The human BM-MSCs were divided into an experimental group and a control group. A blank group of cells was added with a complete medium without rat serum; an experimental group of cells was added with the prepared drug-containing serum. Under hypoxic conditions, the drug-containing serum was used to treat BM-MSCs and/or endothelial cells of human umbilical vein (HUVECs). A Cell counting kit (CCK8) was used to detect cell proliferation. Western blot (WB) and quantitative real-time PCR (qPCR) were used to identify related genes expression.
RESULTS
The results of this study showed that the purity of the BM-MSCs was >95%. The drug-containing serum significantly rise in CCND1 expression (encoding cyclin D1) and MYC, especially when the concentration of medicated serum was 10.8 g × kg-1 × d-1. Treatment of either BM-MSCs or HUVECs alone or both with medicated serum aids in the spread of mesenchymal stem cells from the bone marrow to HUVECs. qPCR results showed that the mRNA expression of CCL2, CCL3, CCL25, IL8, IGF1, and PDGFB increased dramatically after treatment with medicated serum. The expression of the corresponding receptors for these up-regulated chemokines was detected in BM-MSCs, and it was found that CXCR1, CXCR4, CXCR7, and PDGFRB were up-regulated.
CONCLUSION
This study provides a preliminary understanding of the mechanism of RJQM in the treatment of ASO.
目的
研究（BM-MSCs）对软脉清肝方（RJQM）治疗动脉粥样硬化闭塞症（ASO）的反应，从而促进侧支循环和血管生成。
方法
将 35 只雄性大鼠随机分为 6 个实验组和 A 对照组。实验组大鼠每天 2 次灌胃 0.9%生理盐水和 2.7、5.4、10.8、16.2、21.6、27 g×kg-1×d-1的 RJQM 配方，连续 8 天。末次给药后，从腹主动脉采集血液制备含药血清。将人 BM-MSCs 分为实验组和对照组。空白组细胞加入不含大鼠血清的完全培养基；实验组细胞加入制备的含药血清。在缺氧条件下，用含药血清处理 BM-MSCs 和/或人脐静脉内皮细胞（HUVECs）。细胞计数试剂盒（CCK8）检测细胞增殖。Western blot（WB）和实时定量 PCR（qPCR）鉴定相关基因表达。
结果
本研究结果表明，BM-MSCs 的纯度>95%。含药血清可显著上调 CCND1（编码细胞周期蛋白 D1）和 MYC 的表达，尤其是当含药血清浓度为 10.8 g×kg-1×d-1 时。单独或联合用含药血清处理 BM-MSCs 或 HUVECs 均可促进骨髓间充质干细胞向 HUVECs 扩散。qPCR 结果显示，含药血清处理后，CCL2、CCL3、CCL25、IL8、IGF1 和 PDGFB 的 mRNA 表达显著增加。在 BM-MSCs 中检测到这些上调趋化因子的相应受体表达，发现 CXCR1、CXCR4、CXCR7 和 PDGFRB 上调。
结论
本研究初步探讨了 RJQM 治疗 ASO 的作用机制。
Zotero 插件